Dynavax Technologies Corporation (0IDA.L)

11,17 -0,03 (-0,26%) Alla chiusura: 02:55PM BST

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 408

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Ryan Spencer	CEO, Interim CFO & Director	1,49M	N/D	1978
Mr. David F. Novack	President & COO	1,01M	1,51M	1962
Dr. Robert Janssen M.D.	Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs	861,52k	251,32k	1954
Ms. Kelly MacDonald	Senior VP & CFO (Leave of Absence)	788,55k	N/D	1984
Mr. Justin Burgess	Chief Accounting Officer & Controller	N/D	N/D	N/D
Mr. Jeff P. Coon	Senior VP & Chief Human Resources Officer	N/D	N/D	1963
Mr. Paul Cox	VP of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. John L. Slebir	Senior VP & General Counsel	N/D	N/D	1966
Mr. Donn Casale	Senior VP & Chief Commercial Officer	N/D	N/D	N/D
Dr. Dong Yu	Senior Vice President of Vaccine Research	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Governance aziendale

L'ISS Governance QualityScore di Dynavax Technologies Corporation al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 7; retribuzione: 3.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.